Antimicrobial treatment of ventilator-associated pneumonia

Respiratory Care

Volumn 50, Issue 7, 2005, Pages 932-952

  Park, David R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antibiotic; Antibiotic resistant; Antimicrobial; Antimicrobial resistant; Mechanical ventilation; Nosocomial; Pharmacodynamic; Pharmacokinetic; Pneumonia; Review; Treatment; Ventilator associated pneumonia

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; LINCOSAMIDE DERIVATIVE; LINEZOLID; MACROLIDE; MEROPENEM; METRONIDAZOLE; MONOBACTAM; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAMYCIN; STREPTOGRAMIN DERIVATIVE; SULFAMETHOXAZOLE; SULFONAMIDE; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTIFICIAL VENTILATION; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; GRAM STAINING; HEALTH CARE COST; HUMAN; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; REPEATED DRUG DOSE; RESPIRATORY FAILURE; RISK FACTOR; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA; BACTERIAL PNEUMONIA; CLASSIFICATION; DOSE RESPONSE; REVIEW; UNITED STATES; VENTILATOR;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; HUMANS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES; UNITED STATES; VENTILATORS, MECHANICAL;

EID: 26944472454     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (136)

1. Park DR. Microbiology of ventilator-associated pneumonia. Respir Care 2005;50(6):742-765.
2. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32(8):470-485.
3. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165(7):867-903.
4. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416.
5. Kollef MH. The importance of appropriate initial antibiotic therapy for hospital-acquired infections. Am J Med 2003;115(7):582-584.
6. Yu VL, Singh N. Excessive antimicrobial usage causes measurable harm to patients with suspected ventilator-associated pneumonia. Intensive Care Med 2004;30(5):735-738.
7. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26(1):1-10.
8. Zhanel GG. Influence of pharmacokinetic and pharmacodynamic principles on antibiotic selection. Curr Infect Dis Rep 2001;3(1): 29-34.
9. Leggett JE, Fantin B, Ebert S, Totsuka K, Vogelman B, Calame W, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonias and thigh-infection models. J Infect Dis 1989;159(2):281-292.
10. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37(5):1073-1081.
11. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother 1999;43(3):623-629.
12. Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 2003; 52(4):668-674.
13. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22(1-2):89-96.
14. Ambrose PG, Owens RC Jr, Garvey MJ, Jones RN. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother 2002; 49(3):445-453.
15. Bernabeu-Wittel M, Garcia-Curiel A, Pichardo C, Pachon-Ibanez ME, Jimenez-Mejias ME, Pachon J. Morphological changes induced by imipenem and meropenem at sub-inhibitory concentrations in Acinetobacter baumannii. Clin Microbiol Infect 2004; 10(10):931-934.
16. McDonald PJ, Wetherall BL, Pruul H. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 1981;3(1):38-44.
17. Pruul H, Wetherall BL, McDonald PJ. Enhanced susceptibility of Escherichia coli to intracellular killing by human polymorphonuclear leukocytes after in vitro incubation with chloramphenicol. Antimicrob Agents Chemother 1981;19(6):945-951.
18. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992;36(12):2577-2583.
19. Boselli E, Breilh D, Rimmele T, Poupelin JC, Saux MC, Chassard D, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004;30(5):989-991.
20. Fraschini F, Nebuloni R, Cortelazzi R, Falchi M. Antibiotics and mucous membrane: pharmacokinetic aspects. J Chemother 1991;3 Suppl 1:182-189.
21. Cunha BA, Gerding DN. Introduction: antimicrobial penetration into respiratory secretions. Semin Respir Infect 1991;6(2):67-68.
22. Honeybourne D. Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Curr Opin Pulm Med 1997;3(2):170-174.
23. Nix DE. Intrapulmonary concentrations of antimicrobial agents. Infect Dis Clin North Am 1998;12(3):631-646.
24. Cazzola M, Blasi F, Terzano C, Matera MG, Marsico SA. Delivering antibacterials to the lungs: considerations for optimizing outcomes. Am J Respir Med 2002;1(4):261-272.
25. Honeybourne D, Rews JM, Ashby JP, Lodwick R, Wise R. Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa. Thorax 1988;43(9):715-719.
26. Deere D, Bergogne-Berezin E. Pharmacokinetics of quinolones with special reference to the respiratory tree. J Antimicrob Chemother 1993;31(3):331-343.
27. Olsen KM, San Pedro G, Gann LP, Gubbins PO, Halinski DM, Campbell GD Jr. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother 1996;40(11):2582-2585.
28. Herkner H, Muller MR, Kreischitz N, Mayer BX, Frossard M, Joukhadar C, et al. Closed-chest microdialysis to measure antibiotic penetration into human lung tissue. Am J Respir Crit Care Med 2002;165(2):273-276.
29. Tomaselli F, Dittrich P, Maier A, Woltsche M, Matzi V, Pinter J, et al. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis. Br J Clin Pharmacol 2003;55(6):620-624.
30. Tomaselli F, Maier A, Matzi V, Smolle-Juttner FM, Dittrich P. Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Antimicrob Agents Chemother 2004;48(6):2228-2232.
31. Campbell BD, Kadner RJ. Relation of aerobiosis and ionic strength to the uptake of dihydrostreptomycin in Escherichia coli. Biochim Biophys Acta 1980;593(1):1-10.
32. Schlessinger D. Failure of aminoglycoside antibiotics to kill anaerobic, low-pH, and resistant cultures. Clin Microbiol Rev 1988;1(1): 54-59.
33. CO2 on the activity of antimicrobial agents in vitro. Eur J Clin Microbiol Infect Dis 1993;12(7):519-526.
34. Tresse O, Jouenne T, Junter GA. The role of oxygen limitation in the resistance of agar-entrapped, sessile-like Escherichia coli to aminoglycoside and beta-lactam antibiotics. J Antimicrob Chemother 1995;36(3):521-526.
35. Sottile FD, Marrie TJ, Prough DS, Hobgood CD, Gower DJ, Webb LX, et al. Nosocomial pulmonary infection: possible etiologic significance of bacterial adhesion to endotracheal tubes. Crit Care Med 1986;14(4):265-270.
36. Adair CG, Gorman SP, Feron BM, Byers LM, Jones DS, Goldsmith CE, et al. Implications of endotracheal tube biofilm for ventilator-associated pneumonia. Intensive Care Med 1999;25(10):1072-1076.
37. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomoms aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004; 42(5):1915-1922.
38. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999;20(2):303-316.
39. Fridkin SK, Hill HA, Volkova NV, Edwards JR, Lawton RM, Gaynes RP, et al. Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 2002;8(7):697-701.
40. Szabo D, Silveira F, Fujitani S, Paterson DL. Mechanisms of resistance of bacteria causing ventilator-associated pneumonia. Clin Chest Med 2005;26(1):75-79.
41. Clark NM, Hershberger E, Zervosc MJ, Lynch JP 3rd. Antimicrobial resistance among Gram-positive organisms in the intensive care unit. Curr Opin Crit Care 2003;9(5):403-412.
42. Clark NM, Patterson J, Lynch JP 3rd. Antimicrobial resistance among Gram-negative organisms in the intensive care unit. Curr Opin Crit Care 2003;9(5):413-423.
43. Kollef M, Niederman M. Antimicrobial resistance in the ICU: the time for action is now. Crit Care Med 2001;29(4 Suppl):N63.
44. Carlet J, Ben Ali A, Chalfine A. Epidemiology and control of antibiotic resistance in the intensive care unit. Curr Opin Infect Dis 2004;17(4):309-316.
45. Nathan C. Antibiotics at the crossroads. Nature 2004;431(7011): 899-902.
46. Walsh FM, Amyes SG. Microbiology and drug resistance mechanisms of fully resistant pathogens. Curr Opin Microbiol 2004;7(5): 439-444.
47. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001;134(4):298-314.
48. Kollef MH, Sherman G, Ward S, Eraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115(2):462-474.
49. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996;22(5): 387-394.
50. Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111(3):675-685.
51. Rello J, Gallego M, Mariscal D, Sonora R, Valles J. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156(1):196-200.
52. Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, El-Ebiary M, Carrillo A, Ruiz J, et al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study. Am J Respir Crit Care Med 1998;157(2):371-376.
53. Ruiz M, Torres A, Ewig S, Marcos MA, Alcon A, Lledo R, et al. Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. Am J Respir Crit Care Med 2000; 162(1): 119-125.
54. Ibrahim EH, Ward S, Sherman G, Kollef MH. A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 2000; 117(5): 1434-1442.
55. Iregui M, Ward S, Sherman G, Eraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122(1):262-268.
56. Dupont H, Mentec H, Sollet JP, Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001;27(2):355-362.
57. Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002;122(6):2183-2196.
58. Fagon JY. Hospital-acquired pneumonia: diagnostic strategies: lessons from clinical trials. Infect Dis Clin North Am 2003;17(4):717-726.
59. Rello J, Diaz E. Pneumonia in the intensive care unit. Crit Care Med 2003;31(10):2544-2551.
60. Kollef MH. Treatment of ventilator-associated pneumonia: get it right from the start. Crit Care Med 2003;31(3):969-970.
61. Fagon JY, Chastre J. Antimicrobial treatment of hospital-acquired pneumonia. Clin Chest Med 2005;26(1):97-104.
62. Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stephan F, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: a randomized trial. Ann Intern Med 2000;132(8):621-630.
63. Luna CM, Chirino A. Qualitative cultures in ventilator-associated pneumonia: can they be used with confidence? Crit Care 2004;8(6): 425-426.
64. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157(2):531-539.
65. Ost DE, Hall CS, Joseph G, Ginocchio C, Condon S, Kao E, et al. Decision analysis of antibiotic and diagnostic strategies in ventilator-associated pneumonia. Am J Respir Crit Care Med 2003;168(9): 1060-1067.
66. Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999;160(2):608-613.
67. Namias N, Samiian L, Nino D, Shirazi E, O'Neill K, Kett DH, et al. Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies. J Trauma 2000;49(4):638-645; discussion 645-646.
68. Babcock HM, Zack JE, Garrison T, Trovillion E, Kollef MH, Eraser VJ. Ventilator-associated pneumonia in a multi-hospital system: differences in microbiology by location. Infect Control Hosp Epidemiol 2003;24(11):853-858.
69. Hayon J, Figliolini C, Combes A, Trouillet JL, Kassis N, Dombret MC, et al. Role of serial routine microbiologic culture results in the initial management of ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165(1):41-46.
70. Rello J, Lorente C, Diaz E, Bodi M, Boque C, Sandiumenge A, et al. Incidence, etiology, and outcome of nosocomial pneumonia in ICU patients requiring percutaneous tracheotomy for mechanical ventilation. Chest 2003;124(6):2239-2243.
71. Michel F, Franceschini B, Berger P, Arnal JM, Gainnier M, Sainty JM, et al. Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. Chest 2005;127(2):589-597.
72. Blot S, Vandewoude K, Hoste E, Colardyn F. Tracheal colonization in pneumonia (letter). Chest 2000;117(4):1216.
73. Marquette CH, Wallet F, Neviere R, Copin MC, Saulnier F, Drault JN, et al. Diagnostic value of direct examination of the protected specimen brush in ventilator-associated pneumonia. Eur Respir J 1994;7(1):105-113.
74. Mertens AH, Nagler JM, Galdermans DI, Slabbynck HR, Weise BS, Coolen D. Diagnostic value of direct examination of protected specimen brush samples in nosocomial pneumonia. Eur J Clin Microbiol Infect Dis 1996;15(10):807-810.
75. Prekates A, Nanas S, Argyropoulou A, Margariti G, Kyprianou T, Papagalos E, et al. The diagnostic value of Gram stain of bronchoalveolar lavage samples in patients with suspected ventilator-associated pneumonia. Scand J Infect Dis 1998;30(1):43-47.
76. Kollef MH, Eisenberg PR, Ohlendorf MF, Wick MR. The accuracy of elevated concentrations of endotoxin in bronchoalveolar lavage fluid for the rapid diagnosis of Gram-negative pneumonia. Am J Respir Crit Care Med 1996;154(4 Pt 1):1020-1028.
77. Allaouchiche B, Jaumain H, Dumontet C, Motin J. Early diagnosis of ventilator-associated pneumonia. Is it possible to define a cutoff value of infected cells in BAL fluid? Chest 1996;110(6):1558-1565.
78. Papazian L, Autillo-Touati A, Thomas P, Bregeon F, Garbe L, Saux P, et al. Diagnosis of ventilator-associated pneumonia: an evaluation of direct examination and presence of intracellular organisms. Anesthesiology 1997;87(2):268-276.
79. Croce MA, Fabian TC, Waddle-Smith L, Melton SM, Minard G, Kudsk KA, et al. Utility of Gram's stain and efficacy of quantitative cultures for posttraumatic pneumonia: a prospective study. Ann Surg 1998;227(5):743-751; discussion 751-755.
80. Allaouchiche B, Jaumain H, Chassard D, Bouletreau P. Gram stain of bronchoalveolar lavage fluid in the early diagnosis of ventilator-associated pneumonia. Br J Anaesth 1999;83(6):845-849.
81. Mimoz O, Karim A, Mazoit JX, Edouard A, Leprince S, Nordmann P. Gram staining of protected pulmonary specimens in the early diagnosis of ventilator-associated pneumonia. Br J Anaesth 2000; 85(5):735-739.
82. Duflo F, Allaouchiche B, Debon R, Bordet F, Chassard D. An evaluation of the Gram stain in protected bronchoalveolar lavage fluid for the early diagnosis of ventilator-associated pneumonia. Anesth Analg 2001;92(2):442-447.
83. Davis KA, Eckert MJ, Reed RL 2nd, Esposito TJ, Santaniello JM, Poulakidas S, et al. Ventilator-associated pneumonia in injured patients: do you trust your Gram's stain? J Trauma 2005;58(3):462-466; discussion 466-467.
84. Timsit JF, Cheval C, Gachot B, Bruneel F, Wolff M, Carlet J, et al. Usefulness of a strategy based on bronchoscopy with direct examination of bronchoalveolar lavage fluid in the initial antibiotic therapy of suspected ventilator-associated pneumonia. Intensive Care Med 2001;27(4):640-647.
85. Chastre J, Trouillet JL. Problem pathogens (Pseudomonas aeruginosa and Acinetobacter). Semin Respir Infect 2000;15(4):287-298.
86. Rello J, Torres A, Ricart M, Valle;s J, Gonzalez J, Artigas A, et al. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994;150(6 Pt 1):1545-1549.
87. Pujol M, Corbella X, Pena C, Pallares R, Dorca J, Verdaguer R, et al. Clinical and epidemiological findings in mechanically-ventilated patients with methicillin-resistant Staphylococcus aureus pneumonia. Eur J Clin Microbiol Infect Dis 1998;17(9):622-628.
88. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124(5):1789-1797.
89. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30(3):388-394.
90. Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 2004;32(1):137-143.
91. Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 1999;58(6):1061-1097.
92. Anstead GM, Owens AD. Recent advances in the treatment of infections due to resistant Staphylococcus aureus. Curr Opin Infect Dis 2004;17(6):549-555.
93. Guay DR. Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy 2004;24(1): 58-68.
94. Montero A, Ariza J, Corbella X, Domenech A, Cabellos C, Ayats J, et al. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002;46(6):1946- 1952.
95. Montero A, Ariza J, Corbella X, Domenech A, Cabellos C, Ayats J, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004;54(6):1085-1091.
96. Wolff M, Joly-Guillou ML, Farinotti R, Carbon C. In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother 1999;43(6):1406-1411.
97. Tascini C, Menichetti F, Bozza S, Del Favero A, Bistoni F. Evaluation of the activities of two-drug combinations of rifampicin, polymyxin b and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother 1998;42(2):270-271.
98. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002;34(11):1425-1430.
99. Wood GC, Hanes SD, Boucher BA, Croce MA, Fabian TC. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator- associated pneumonia. Intensive Care Med 2003;29(11): 2072-2076.
100. Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28(5):1008-1011.
101. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003;37(11):154-160.
102. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with icu-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005;11(2):115-121.
103. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittel IM, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36(9):1111-1118.
104. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, Llanos AC, Pachon J. Activity of tigecycline (gar-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004;48(11):4479-4481.
105. Roig J, Rello J. Legionnaires' disease: a rational approach to therapy. J Antimicrob Chemother 2003;51(5):1119-1129.
106. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996;153(5):1711-1725.
107. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162(2Pt 1):505-511.
108. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290(19):2588-2598.
109. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001;29(6):1109-1115.
110. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004;125(5):1791-1799.
111. Rello J, Vidaur L, Sandiumenge A, Rodriguez A, Gualis B, Boque C, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004;32(11):2183-2190.
112. Bernabeu-Wittel M, Pichardo C, Garcia-Curiel A, Pachon-Ibanez ME, Ibanez-Martinez J, Jimenez-Mejias ME, et al. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect 2005;11(4):319-325.
113. Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994;38(6):1309-1313.
114. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328(7441):668.
115. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004;4(8):519-527.
116. Kollef MH, Vlasnik J, Sharpless L, Pasque C, Murphy D, Fraser V. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156(4 Pt 1):1040-1048.
117. Gruson D, Hilbert G, Vargas F, Valentino R, Bebear C, Allery A, et al. Rotation and restricted use of antibiotics in a medical intensive care unit: impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Am J Respir Crit Care Med 2000;162(3 Pt 1):837-843.
118. Raymond DP, Pelletier SJ, Crabtree TD, Gleason TG, Hamm LL, Pruett TL, et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med 2001; 29(6):1101-1108.
119. Allegranzi B, Luzzati R, Luzzani A, Girardini F, Antozzi L, Raiteri R, et al. Impact of antibiotic changes in empirical therapy on antimicrobial resistance in intensive care unit-acquired infections. J Hosp Infect 2002;52(2):136-140.
120. Gruson D, Hilbert G, Vargas F, Valentino R, Bui N, Pereyre S, et al. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 2003;31(7):1908-1914.
121. Warren DK, Hill HA, Merz LR, Kollef MH, Hayden MK, Fraser VJ, et al. Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. Crit Care Med 2004;32(12):2450-2456.
122. Levin BR, Bonten MJ. Cycling antibiotics may not be good for your health. Proc Natl Acad Sci USA 2004;101(36):13101-13102.
123. Brown EM, Nathwani D. Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. J Antimicrob Chemother 2005;55(1):6-9.
124. Rouby JJ, Poete P, Martin de Lassale E, Nicolas MH, Bodin L, Jarlier V, et al. Prevention of Gram negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients: histologic and bacteriologic study. Intensive Care Med 1994;20(3):187-192.
125. Wood GC, Boucher BA, Croce MA, Hanes SD, Herring VL, Fabian TC. Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients. Pharmacotherapy 2002;22(8):972-982.
126. Adair CG, Gorman SP, Byers LM, Jones DS, Feron B, Crowe M, et al. Eradication of endotracheal tube biofilm by nebulised gentamicin. Intensive Care Med 2002;28(4):426-431.
127. Klepser ME. Role of nebulized antibiotics for the treatment of respiratory infections. Curr Opin Infect Dis 2004;17(2):109-112.
128. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000;162(1):328-330.
129. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9(1): 53-59.
130. Brown RB, Kruse JA, Counts GW, Russell JA, Christou NV, Sands ML. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The endotracheal tobramycin study group. Antimicrob Agents Chemother 1990;34(2): 269-272.
131. Franz AR, Rohlke W, Franke RP, Ebsen M, Pohlandt F, Hummler HD. Pulmonary administration of perfluorodecaline-gentamicin and perfluorodecaline-vancomycin emulsions. Am J Respir Crit Care Med 2001;164(9):1595-1600.
132. Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 2004; 125(2 Suppl):62S-69S.
133. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003;123(5):1495-1502.
134. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290(13):1749-1756.
135. Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005; 18(2):125-131.
136. Craig WA. Proof of concept: performance testing in models. Clin Microbiol Infect 2004;10 Suppl 2:12-17.